Business Weekly reported in March that the company would be looking to generate more growth funding despite having $339.2 million cash – a runway to take the Nasdaq-quoted company into 2025.
The company has grown headcount and facilities in the UK and in the Boston cluster in the US and its drug pipeline is accelerating fast.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,